ERBB2 and neoplasm: Our analysis found that after IPTW adjustment for potentially confounding demographic and clinical characteristics, tumor burden endpoints such as rwPFS and rwRR derived from curated real-world data were similar to those observed in an RCT in women treated with letrozole monotherapy as first-line treatment for HR+/HER2– mBC.